Literature DB >> 20512607

Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor.

Pepijn Vemer1, Maureen P M H Rutten-van Mölken.   

Abstract

Recently, several checklists systematically assessed factors that affect the transferability of cost-effectiveness (CE) studies between jurisdictions. The role of the threshold value for a QALY has been given little consideration in these checklists, even though the importance of a factor as a cause of between country differences in CE depends on this threshold. In this paper, we study the impact of the willingness-to-pay (WTP) per QALY on the importance of transferability factors in the case of smoking cessation support (SCS). We investigated, for several values of the WTP, how differences between six countries affect the incremental net monetary benefit (INMB) of SCS. The investigated factors were demography, smoking prevalence, mortality, epidemiology and costs of smoking-related diseases, resource use and unit costs of SCS, utility weights and discount rates. We found that when the WTP decreased, factors that mainly affect health outcomes became less important and factors that mainly effect costs became more important. With a WTP below <euro>1,000, the factors most responsible for between country differences in INMB were resource use and unit costs of SCS and the costs of smoking-related diseases. Utility values had little impact. At a threshold above <euro>10,000, between country differences were primarily due to different discount rates, utility weights and epidemiology of smoking-related diseases. Costs of smoking-related diseases had little impact. At all thresholds, demography had little impact. We concluded that, when judging the transferability of a CE study, we should consider the between country differences in WTP threshold values.

Entities:  

Mesh:

Year:  2010        PMID: 20512607      PMCID: PMC3160548          DOI: 10.1007/s10198-010-0253-3

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  16 in total

1.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

Review 2.  Can economic evaluations be made more transferable?

Authors:  Stephanie Boulenger; John Nixon; Michael Drummond; Philippe Ulmann; Stephen Rice; Gerard de Pouvourville
Journal:  Eur J Health Econ       Date:  2005-12

Review 3.  Antidepressants for smoking cessation.

Authors:  J R Hughes; L F Stead; T Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.

Authors:  Martine Hoogendoorn; Paco Welsing; Maureen P M H Rutten-van Mölken
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580

5.  Guidelines for completing the EURONHEED transferability information checklists.

Authors:  John Nixon; Stephen Rice; Michael Drummond; Stephanie Boulenger; Philippe Ulmann; Gerard de Pouvourville
Journal:  Eur J Health Econ       Date:  2008-07-11

6.  Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.

Authors:  Pepijn Vemer; Maureen P M H Rutten-van Mölken
Journal:  Value Health       Date:  2009-09-25       Impact factor: 5.725

7.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

8.  Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom.

Authors:  M J Thun; L F Apicella; S J Henley
Journal:  JAMA       Date:  2000-08-09       Impact factor: 56.272

9.  Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.

Authors:  Kristian Bolin; Ann-Christin Mörk; Stefan Willers; Björn Lindgren
Journal:  Respir Med       Date:  2008-03-04       Impact factor: 3.415

10.  Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.

Authors:  Paul Howard; Christopher Knight; Annabel Boler; Christine Baker
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more
  6 in total

1.  Health economics and health technology assessment in Central and Eastern Europe: a dose of reality.

Authors:  L Gulácsi; E Orlewska; M Péntek
Journal:  Eur J Health Econ       Date:  2012-10

Review 2.  Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.

Authors:  María Buti; Itziar Oyagüez; Virginia Lozano; Miguel A Casado
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

3.  Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.

Authors:  Barnaby Hunt; Samuel J P Malkin; Robert G J Moes; Eline L Huisman; Tom Vandebrouck; Bruce H R Wolffenbuttel
Journal:  BMJ Open Diabetes Res Care       Date:  2019-10-01

4.  Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis.

Authors:  Maria V Aviles-Blanco
Journal:  Health Econ Rev       Date:  2021-07-23

5.  Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives.

Authors:  Jill Bindels; Bram Ramaekers; Isaac Corro Ramos; Leyla Mohseninejad; Saskia Knies; Janneke Grutters; Maarten Postma; Maiwenn Al; Talitha Feenstra; Manuela Joore
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

6.  A utility of model input uncertainty analysis in transferring tobacco control-related economic evidence to countries with scarce resources: results from the EQUIPT study.

Authors:  Bertalan Németh; Puttarin Kulchaitanaroaj; Adam Lester-George; Mirjana Huic; Kathryn Coyle; Doug Coyle; Subhash Pokhrel; Zoltán Kaló
Journal:  Addiction       Date:  2018-01-28       Impact factor: 6.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.